Krystal Biotech Reports Strong Q4 2025 Revenue and Clinical Pipeline Expansion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Source: Investing
Krystal Biotech's stock has surged by 7.03%, reaching a 52-week high amid a broader market decline, with the Nasdaq-100 down 0.40% and the S&P 500 down 0.42%.
The company reported anticipated Q4 2025 net revenue for VYJUVEK between $106 million and $107 million, with full-year revenue projected at $388 million to $389 million, showcasing its strong market potential in rare disease therapies. Additionally, Krystal plans to expand its clinical trial for KB801, increasing patient enrollment from 27 to 60, which reflects its commitment to addressing unmet medical needs in rare diseases.
This robust financial performance and strategic clinical development are likely to enhance investor confidence and position Krystal Biotech favorably in the competitive landscape of rare disease treatments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KRYS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KRYS
Wall Street analysts forecast KRYS stock price to fall
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 341.660
Low
198.00
Averages
229.25
High
278.00
Current: 341.660
Low
198.00
Averages
229.25
High
278.00
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three Stocks Thriving Amid Economic Headwinds
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine, mRNA-1010, aimed at addressing the low effectiveness of current flu vaccines, particularly for the elderly, which could significantly enhance its competitive position in the vaccine market.
- Krystal Biotech Strong Performance: Krystal Biotech has achieved positive earnings for 11 consecutive quarters with its gene therapy Vyjuvek, and as it expands into new markets in Europe, its revenue is expected to continue growing, showcasing its strong potential in the biotech sector.
- AMD Market Share Growth: AMD's stock has surged 129% year-to-date, with its desktop CPU market share rising to 33.2% and achieving a record 46.2% revenue share, indicating its strong competitive edge and pricing power in the AI sector.
- AI Market Opportunities: With the rise of agentic AI systems, AMD's EPYC processors are positioned as leaders in the server CPU market, potentially benefiting from a $200 billion market opportunity, further solidifying its industry standing.
See More
Investment Outlook for Moderna, Krystal Biotech, and AMD
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine mRNA-1010, which addresses a critical need for effective vaccines among the elderly, potentially enhancing the company's market position and financial performance significantly.
- Krystal Biotech Growth Potential: Krystal Biotech has achieved 11 consecutive quarters of earnings growth with its gene therapy Vyjuvek for a rare disease, and it still has a large addressable market to explore, with upcoming clinical data likely to further boost its stock price.
- AMD Market Leadership: AMD's stock has soared 129% year-to-date, and its leadership in the server CPU market positions it well to capitalize on the rapidly growing artificial intelligence sector, which is expected to continue driving revenue and market share growth.
- Economic and Market Performance: Despite economic and geopolitical challenges, the S&P 500 has risen 8% so far this year, demonstrating overall market resilience, with standout performances from companies like Moderna, Krystal Biotech, and AMD, making them attractive investment options.
See More
Three Stocks Outperforming the Market
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine mRNA-1010, which could significantly improve health outcomes for elderly patients and meet the urgent market need for effective vaccines, potentially leading to stronger financial performance over the next two years.
- Krystal Biotech Growth Momentum: Krystal Biotech has achieved positive earnings for 11 consecutive quarters with its gene therapy Vyjuvek for a rare disease, and it is expected to continue expanding its market presence while launching more clinical trial candidates, driving sustained revenue growth.
- AMD Market Leadership: AMD's stock has surged 129% year-to-date, with its desktop CPU market share reaching 33.2% and a record revenue share of 46.2%, showcasing its strong competitive position in the rapidly growing artificial intelligence sector.
- Optimistic Investment Outlook: Despite significant stock price increases for Moderna, Krystal Biotech, and AMD, they are still viewed as worthwhile investments, with potential for higher returns in the future, particularly against the backdrop of ongoing innovation and market expansion in their respective fields.
See More
Futures Rise on Iran Deal Hopes Amid Oil Price Drop
- Futures Market Surge: Futures prices have risen on optimistic expectations surrounding a potential Iran deal, indicating increased market confidence in future economic recovery, which may attract more investors.
- Significant Oil Price Drop: Oil prices have sharply declined due to expectations of restored Iranian oil supply, which will impact the global energy market's supply-demand balance and could pressure profits for related companies.
- SpaceX IPO Trading Launch: The SpaceX IPO is set to begin trading, expected to draw significant investor interest, potentially bringing new capital inflows to the company and driving its future growth.
- Increased Market Volatility: With the sharp fluctuations in futures and oil prices, investors need to closely monitor market dynamics to adjust their investment strategies promptly and seize potential profit opportunities.
See More
Trump Cancels Iran Strikes, Markets Rally
- Market Rally: Trump's cancellation of military strikes against Iran led to a jump in the S&P 500 and Nasdaq, although they remain below key levels, indicating market sensitivity to geopolitical risks.
- SpaceX IPO Pricing: SpaceX's IPO is priced at $135 per share, marking a significant step for the company in the capital markets, which is expected to provide funding for future expansion and R&D efforts.
- CrowdStrike Buy Signal: Cybersecurity firm CrowdStrike flashed a new buy signal, indicating market confidence in its growth potential, which may attract more investors to its stock performance.
- Investor Sentiment Fluctuations: Despite the market rebound due to Trump's decision, overall investor sentiment remains influenced by geopolitical and economic data, reflecting uncertainty and volatility in the market.
See More
ACT Capital Management Acquires New Position in Alumis Worth $4.36 Million
- New Position: On May 8, 2026, ACT Capital Management disclosed a new position in Alumis by acquiring 174,250 shares valued at approximately $4.36 million, indicating strong confidence in the company's future prospects.
- Quarterly Valuation: The position's valuation stood at $3.84 million at quarter-end, reflecting the impact of market price changes and share count, highlighting Alumis's significance in the investment portfolio.
- Stock Performance: Alumis shares surged 350% over the past year, significantly outperforming the S&P 500's 30% gain, showcasing its robust growth potential in the biopharmaceutical sector.
- Clinical Progress: Alumis reported positive Phase 3 data for moderate-to-severe plaque psoriasis in March, with plans to submit a New Drug Application in the second half of 2026, further boosting investor confidence in its drug development pipeline.
See More
Three Stocks Thriving Amid Economic Headwinds
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine, mRNA-1010, aimed at addressing the low effectiveness of current flu vaccines, particularly for the elderly, which could significantly enhance its competitive position in the vaccine market.
- Krystal Biotech Strong Performance: Krystal Biotech has achieved positive earnings for 11 consecutive quarters with its gene therapy Vyjuvek, and as it expands into new markets in Europe, its revenue is expected to continue growing, showcasing its strong potential in the biotech sector.
- AMD Market Share Growth: AMD's stock has surged 129% year-to-date, with its desktop CPU market share rising to 33.2% and achieving a record 46.2% revenue share, indicating its strong competitive edge and pricing power in the AI sector.
- AI Market Opportunities: With the rise of agentic AI systems, AMD's EPYC processors are positioned as leaders in the server CPU market, potentially benefiting from a $200 billion market opportunity, further solidifying its industry standing.
See More
Investment Outlook for Moderna, Krystal Biotech, and AMD
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine mRNA-1010, which addresses a critical need for effective vaccines among the elderly, potentially enhancing the company's market position and financial performance significantly.
- Krystal Biotech Growth Potential: Krystal Biotech has achieved 11 consecutive quarters of earnings growth with its gene therapy Vyjuvek for a rare disease, and it still has a large addressable market to explore, with upcoming clinical data likely to further boost its stock price.
- AMD Market Leadership: AMD's stock has soared 129% year-to-date, and its leadership in the server CPU market positions it well to capitalize on the rapidly growing artificial intelligence sector, which is expected to continue driving revenue and market share growth.
- Economic and Market Performance: Despite economic and geopolitical challenges, the S&P 500 has risen 8% so far this year, demonstrating overall market resilience, with standout performances from companies like Moderna, Krystal Biotech, and AMD, making them attractive investment options.
See More
Three Stocks Outperforming the Market
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine mRNA-1010, which could significantly improve health outcomes for elderly patients and meet the urgent market need for effective vaccines, potentially leading to stronger financial performance over the next two years.
- Krystal Biotech Growth Momentum: Krystal Biotech has achieved positive earnings for 11 consecutive quarters with its gene therapy Vyjuvek for a rare disease, and it is expected to continue expanding its market presence while launching more clinical trial candidates, driving sustained revenue growth.
- AMD Market Leadership: AMD's stock has surged 129% year-to-date, with its desktop CPU market share reaching 33.2% and a record revenue share of 46.2%, showcasing its strong competitive position in the rapidly growing artificial intelligence sector.
- Optimistic Investment Outlook: Despite significant stock price increases for Moderna, Krystal Biotech, and AMD, they are still viewed as worthwhile investments, with potential for higher returns in the future, particularly against the backdrop of ongoing innovation and market expansion in their respective fields.
See More
Futures Rise on Iran Deal Hopes Amid Oil Price Drop
- Futures Market Surge: Futures prices have risen on optimistic expectations surrounding a potential Iran deal, indicating increased market confidence in future economic recovery, which may attract more investors.
- Significant Oil Price Drop: Oil prices have sharply declined due to expectations of restored Iranian oil supply, which will impact the global energy market's supply-demand balance and could pressure profits for related companies.
- SpaceX IPO Trading Launch: The SpaceX IPO is set to begin trading, expected to draw significant investor interest, potentially bringing new capital inflows to the company and driving its future growth.
- Increased Market Volatility: With the sharp fluctuations in futures and oil prices, investors need to closely monitor market dynamics to adjust their investment strategies promptly and seize potential profit opportunities.
See More
Trump Cancels Iran Strikes, Markets Rally
- Market Rally: Trump's cancellation of military strikes against Iran led to a jump in the S&P 500 and Nasdaq, although they remain below key levels, indicating market sensitivity to geopolitical risks.
- SpaceX IPO Pricing: SpaceX's IPO is priced at $135 per share, marking a significant step for the company in the capital markets, which is expected to provide funding for future expansion and R&D efforts.
- CrowdStrike Buy Signal: Cybersecurity firm CrowdStrike flashed a new buy signal, indicating market confidence in its growth potential, which may attract more investors to its stock performance.
- Investor Sentiment Fluctuations: Despite the market rebound due to Trump's decision, overall investor sentiment remains influenced by geopolitical and economic data, reflecting uncertainty and volatility in the market.
See More
ACT Capital Management Acquires New Position in Alumis Worth $4.36 Million
- New Position: On May 8, 2026, ACT Capital Management disclosed a new position in Alumis by acquiring 174,250 shares valued at approximately $4.36 million, indicating strong confidence in the company's future prospects.
- Quarterly Valuation: The position's valuation stood at $3.84 million at quarter-end, reflecting the impact of market price changes and share count, highlighting Alumis's significance in the investment portfolio.
- Stock Performance: Alumis shares surged 350% over the past year, significantly outperforming the S&P 500's 30% gain, showcasing its robust growth potential in the biopharmaceutical sector.
- Clinical Progress: Alumis reported positive Phase 3 data for moderate-to-severe plaque psoriasis in March, with plans to submit a New Drug Application in the second half of 2026, further boosting investor confidence in its drug development pipeline.
See More
